Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer
Cyclosporine A sensitizes lung cancer cells to crizotinib through inhibition of the Ca2+/calcineurin/Erk pathway - eBioMedicine
![Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation [Abstract]](https://www.ijbs.com/v16/p2595/toc.jpg "Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation [Abstract]")
Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation [Abstract]
Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers - Lung Cancer
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - Journal of Thoracic Oncology
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression | BMC Cancer | Full Text
Crizotinib inhibits c-MET activation and shows in-vitro efficacy in CRC... | Download Scientific Diagram
Safety and Tolerability of c-MET Inhibitors in Cancer | SpringerLink
Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation - Lung Cancer
Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non–small-cell Lung Cancer - Clinical Lung Cancer
Crizotinib in Patients With MET-Amplified NSCLC - Journal of Thoracic Oncology
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification - Annals of Oncology
Crizotinib inhibits activation of MET pathway caused by MET extracellular SEMA domain duplication - Lung Cancer
ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer: Cell Reports
Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation - Clinical Lung Cancer
PLOS ONE: Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
Crizotinib (PF-02341066) | ALK/c-Met/ROS1阻害剤 | MedChemExpress
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial - Annals of Oncology
PLOS ONE: Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. | Semantic Scholar
Downregulation of MET in H1993 cells, effects of crizotinib on EGFR... | Download Scientific Diagram
Expanding treatment options in NSCLC patients with rare mutations: ALK, ROS1, MET, BRAF - memoinOncology
Effects of crizotinib on ALK/MET phosphorylation, AKT and ERK... | Download Scientific Diagram
Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology | Future Oncology
Crizotinib, a MET inhibitor, prevents peritoneal dissemination in pancreatic cancer
Crizotinib hydrochloride | c-Met 阻害剤
